Home Medicinal chemistry NRG Therapeutics and Domainex partner for drug development project for Parkinson’s disease

NRG Therapeutics and Domainex partner for drug development project for Parkinson’s disease

0

NRG Therapeutics and Domainex aim to develop new small molecule drugs to treat neurodegenerative disorders, such as Parkinson’s disease.

NRG Therapeutics, a UK-based neuroscience company targeting mitochondrial dysfunction, and Domainex, a UK-based integrated drug discovery services company, have formed a collaboration to develop novel disease-modifying drugs to small molecules to treat Parkinson’s disease, motor neurone disease (MND), and other chronic debilitating neurodegenerative disorders.

Under the agreement, Domainex will provide fully integrated lead optimization services, including assay biology and medicinal and computational chemistry, according to a company press release dated June 30, 2022. period of one year, NRG Therapeutics is expected to potentially invest over £1 million (US$1.2 million) in the project. This program follows a £2.68 million (US$3.2 million) Biomedical Catalyst Prize awarded to NRG Therapeutics by Innovate UK.

Previous work by NRG Therapeutics, funded by Parkinson’s Virtual Biotech, the drug development arm of Parkinson’s UK, resulted in the identification of a series of small molecules that inhibit the mitochondrial permeability transition pore (mPTP), a transmembrane protein in mitochondria inner membrane essential for cell signaling and regulation of cell death. Inhibition of mPTP in brain cells has been shown to have neuroprotective benefits, as demonstrated in several preclinical models of Parkinson’s disease and other neurodegenerative diseases, according to the press release.

Previous work by Domainex, which was also funded by Innovate UK, includes a project targeting kinase IκB epsilon/TANK binding kinase 1 for the treatment of inflammatory diseases.

As part of their collaboration, NRG Therapeutics and Domainex will implement an integrated lead optimization program to optimize the pharmaceutical properties of small molecule mPTP inhibitors. Their ultimate goal is to name a preclinical candidate for the treatment of Parkinson’s disease or MND.

“We hope this program will lead to a new treatment for neurodegenerative diseases, such as Parkinson’s disease, which will ultimately benefit patients who desperately need new treatment options for these devastating diseases,” said Tom Mander, CEO of Domainex, in the press release.

“Mitochondrial dysfunction is a common underlying pathology in many degenerative diseases, and there is a substantial body of preclinical data available, which demonstrates that inhibiting mPTP in the brain prevents neuronal cell death, reduces neuroinflammation and prolongs animal survival. We look forward to working with Domainex to advance the development of these compounds into potentially life-changing medicines,” said Neil Miller, co-founder and CEO of NRG Therapeutics, in the release.

Source: Domains